Greenwood Capital Associates LLC trimmed its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 6.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,566 shares of the medical research company’s stock after selling 1,005 shares during the quarter. Greenwood Capital Associates LLC’s holdings in Amgen were worth $2,707,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in the company. Janus Henderson Group PLC increased its stake in shares of Amgen by 3,664.7% during the second quarter. Janus Henderson Group PLC now owns 3,699,351 shares of the medical research company’s stock valued at $637,139,000 after buying an additional 3,601,087 shares during the period. FMR LLC grew its stake in Amgen by 4.8% in the second quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock valued at $9,817,037,000 after purchasing an additional 2,587,041 shares during the last quarter. Renaissance Technologies LLC grew its stake in Amgen by 40.9% in the second quarter. Renaissance Technologies LLC now owns 3,400,145 shares of the medical research company’s stock valued at $585,607,000 after purchasing an additional 986,700 shares during the last quarter. BlackRock Inc. grew its stake in Amgen by 1.9% in the second quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock valued at $8,516,980,000 after purchasing an additional 909,689 shares during the last quarter. Finally, Nordea Investment Management AB grew its stake in Amgen by 12.9% in the second quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock valued at $1,212,602,000 after purchasing an additional 806,119 shares during the last quarter. Institutional investors and hedge funds own 79.53% of the company’s stock.
In related news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction dated Friday, March 16th. The stock was sold at an average price of $189.75, for a total transaction of $289,368.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 4,575 shares of company stock valued at $838,064 in the last ninety days. Corporate insiders own 0.19% of the company’s stock.
Several equities analysts have issued reports on AMGN shares. Oppenheimer set a $205.00 target price on Amgen and gave the company a “buy” rating in a research note on Tuesday, December 12th. Goldman Sachs lowered Amgen from a “conviction-buy” rating to a “buy” rating in a research note on Friday, December 15th. Citigroup lowered Amgen to a “neutral” rating in a research note on Monday, December 18th. Mizuho set a $192.00 target price on Amgen and gave the company a “buy” rating in a research note on Friday, December 22nd. Finally, Piper Jaffray reiterated a “buy” rating on shares of Amgen in a research note on Tuesday, January 2nd. Two analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eleven have given a buy rating to the company. Amgen has a consensus rating of “Hold” and a consensus target price of $190.57.
Shares of Amgen stock traded down $3.86 on Friday, reaching $168.14. 3,747,770 shares of the stock were exchanged, compared to its average volume of 4,476,543. The company has a quick ratio of 5.17, a current ratio of 5.49 and a debt-to-equity ratio of 1.35. Amgen, Inc. has a twelve month low of $152.16 and a twelve month high of $201.23. The company has a market capitalization of $121,155.30, a price-to-earnings ratio of 13.37, a price-to-earnings-growth ratio of 2.06 and a beta of 1.36.
Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, February 1st. The medical research company reported $2.89 EPS for the quarter, missing the Zacks’ consensus estimate of $3.03 by ($0.14). Amgen had a return on equity of 30.87% and a net margin of 8.66%. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.84 billion. During the same period last year, the firm earned $2.89 EPS. The company’s revenue for the quarter was down 2.7% compared to the same quarter last year. research analysts anticipate that Amgen, Inc. will post 13.25 EPS for the current fiscal year.
Amgen declared that its Board of Directors has initiated a share buyback plan on Thursday, February 1st that authorizes the company to repurchase $10.00 billion in shares. This repurchase authorization authorizes the medical research company to purchase shares of its stock through open market purchases. Shares repurchase plans are usually a sign that the company’s management believes its stock is undervalued.
The company also recently announced a quarterly dividend, which will be paid on Friday, June 8th. Investors of record on Thursday, May 17th will be issued a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a dividend yield of 3.14%. The ex-dividend date of this dividend is Wednesday, May 16th. Amgen’s dividend payout ratio (DPR) is 41.97%.
COPYRIGHT VIOLATION NOTICE: “Greenwood Capital Associates LLC Has $2.71 Million Holdings in Amgen, Inc. (AMGN)” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/08/amgen-inc-amgn-stake-lessened-by-greenwood-capital-associates-llc.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.